Infectious Disease

A brief review of the role of bezlotoxumab therapy for patients at high risk for clostridium difficile infection recurrence.

An overview on how the cost of therapy for recurrent clostridium difficile infection may impact treatment planning.

Focused discussion on the use of fidaxomicin for clostridium difficile infection, and possible barriers to the selection of this agent.

Misinformation about flu vaccines must be dealt with immediately, according to Leslie Kantor, PhD, MPH, chair and professor of the Department of Urban-Global Public Health, Rutgers School of Public Health.

Payer participants break down how coverage criteria are determined for treatments for clostridium difficile infection.

Shared insight on the differences between ACG and IDSA/SHEA treatment guidelines for patients with clostridium difficile infection.

Results of a nationwide retrospective cohort study show maternal infection with syphilis, gonorrhea, or chlamydia was associated with an increased risk of preterm birth.

The report briefly explained the policy options that policymakers can use to help address challenges related to vaccine research and development, testing, and manufacturing, as well as the economic challenges related to vaccine development for infectious diseases.

A panel of experts review treatment goals and assessing response in patients with recurrent clostridium difficile infection.

A broad view on the impact of recurrent clostridium difficile infection on patients and the healthcare system at large.

A multifaceted approach focused on enforcing basic infection prevention practices and promoting education about Clostridioides difficile (C difficile) transmission led to a reduction in the number of infections in a hospital setting.

The FDA decision was followed by a CDC advisory panel meeting Friday, and as expected, CDC Director Rochelle Walensky, MD, MPH, who has spoken in favor of booster shots, signed off on the plan.

Experts focus on recurrent clostridium difficile infection to define risk factors and discuss impact on patient outcomes.

Opening their discussion, panelists elucidate patient factors that may impact risk of developing clostridium difficile infection.

Leslie Kantor, PhD, MPH, chair and professor of the Department of Urban-Global Public Health, Rutgers School of Public Health, discusses the key messages that people need to hear about the continued importance of the flu vaccine, even if they have been immunized for COVID-19.

The World Health Organization and CDC warn of the potential for measles outbreaks; the National Institutes of Health (NIH) and Moderna battle over patent rights to Moderna’s COVID-19 vaccine; a new Kaiser Family Foundation shows employers have increased mental health care offerings.

Evidence is insubstantial for treatment of Clostridioides difficile infection (CDI), but authors of a review of available evidence provide recommendations for agents and testing.

The CDC director endorsed a pediatric Pfizer COVID-19 vaccine for children aged 5 to 11 years; proposed drug pricing reform will allow Medicare Part D to negotiate directly with pharmaceutical companies; some employers may not send death benefits to families of employees who die of COVID-19 without being vaccinated.

Peter Hotez, MD, PhD, FASTMH, professor of pediatrics and molecular virology and dean, National School of Tropical Medicine, Baylor College of Medicine, and codirector, Texas Children’s Hospital Center for Vaccine Development, addresses the approval of the Pfizer/BioNTech COVID-19 vaccine for children aged 5 to 11 and emphasized its benefits far outweigh the rare possibility of myocarditis.

In a long-awaited move, the FDA approved a pediatric dose of Pfizer/BioNTech's COVID-19 vaccine for children aged 5 to 11 years.

In studies presented at the American College of Gastroenterology 2021 meeting, success was reported for RBX2660, a treatment for clostridioides difficile infection (CDI).

Many novel traits are shared through gene transfer, but scientists haven’t been able to determine why some bacteria engage in gene transfer while others do not.

A study funded by the National Institutes of Health found that Glucosyltransferase domain is a possible molecular target for therapeutic interventions for Clostridioides difficile infection.

Research presented during IDWeek 2021 showed data on V114, Merck’s investigational 15-valent pneumococcal conjugate vaccine.

Pfizer and BioNTech ask FDA to authorize their COVID-19 vaccine in children; the World Health Organization (WHO) recommended widespread use of the world’s first malaria vaccine; a US judge blocks Texas’ strict abortion law.

Samples from 12 countries suggest shoe soles have a high positivity rate for Clostridium difficile, a strain primarily thought of as a hospital-associated infection.

New research presented at IDWeek 2021 presented data on the microbiota-based live biotherapeutic RBX2660 for recurrent Clostridioides difficile infection.

When patients are quickly readmitted, they have higher health care costs, a new study has found.

The CDC says yes to COVID-19 booster shots; a new survey shows vaccine hesitancy and skepticism are falling; the US Preventive Services Task Force updates screening suggestions for 2 sexually transmitted infections (STIs).

Advanced dementia and serum albumin levels were better predictors of poor outcomes, the investigators said, among older patients with Clostridioides difficile infection (CDI).